Bridge Biotherapeutics, a biotech firm based in South Korea, is poised to emulate the success of Strategy or Metaplanet by implementing a bitcoin treasury approach. The Seongnam-based company has received $183.3 million in funding from Parataxis, a crypto investment firm, which will be used to create a bitcoin reserve. Following the investment, Bridge Biotherapeutics will undergo a name change to Parataxis Korea and continue to be listed on the KOSDAQ stock market.

According to Andrew Kim, a partner at Parataxis, the growing interest in bitcoin treasury strategies, as seen in companies like Strategy in the US and Metaplanet in Japan, is a testament to the increasing global institutional interest in this space. Strategy, which owns over 2.8% of the total bitcoin supply, has inspired numerous companies to adopt a similar approach.

Metaplanet, a Tokyo-listed hotel operator turned bitcoin investor, holds 10,000 BTC, valued at $1.04 billion, making it the largest holding of a public company outside North America. Companies like Strategy and Metaplanet have experienced significant appreciation in their share prices as traders invest in them as a proxy for bitcoin.

Bridge Biotherapeutics joins other healthcare-related companies, such as Semler Scientific and Prenetics Global, in adopting a bitcoin treasury strategy. Parataxis is currently preparing for a public listing in the US via a special purpose acquisition company, SilverBox Corp IV. On Friday, Bridge Biotherapeutics' shares closed 20.5% higher at 943 won ($0.69).